Solara Active Pharma Sciences Limited

NSE:SOLARA.NS

797.9 (INR) • At close November 8, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q22017 Q1
Revenue 3,469.53,634.92,626.42,487.34,252.43,523.13,806.23,947.53,383.73,300.73,230.31,003.44,016.14,055.74,030.64,266.93,975.63,484.22,426.63,436.83,511.33,301.73,207.133,562.33,423.33,028.13,042398.182,585.22
Cost of Revenue 1,718.92,816.61,599.83,041.22,375.31,919.91,924.32,113.91,893.91,956.12,780.6541.61,871.11,784.62,580.51,876.91,741.61,496.81,7121,4821,696.21,517.12,433.331,755.51,760.61,518.41,550241.471,311.17
Gross Profit 1,750.6818.31,026.6-553.91,877.11,603.21,881.91,833.61,489.81,344.6449.7461.82,1452,271.11,450.12,3902,2341,987.4714.61,954.81,815.11,784.6773.81,806.81,662.71,509.71,492156.711,274.05
Gross Profit Ratio 0.5050.2250.391-0.2230.4410.4550.4940.4640.440.4070.1390.460.5340.560.360.560.5620.570.2940.5690.5170.5410.2410.5070.4860.4990.490.3940.493
Reseach & Development Expenses 001,010108110100103959580119135143141140.11381110225.71341100229.310411102700
General & Administrative Expenses 000000680.7000571.2000609.1000557.3000528.5000000
Selling & Marketing Expenses 0000008.60003.80003.100015.600022.8000000
SG&A 610.4649.8736.81,214.6749.6611.5689.3704.1557.6600.7575640624604.4612.2598.8580.1545572.9514.3506.3486.3551.3487.4460.5427.51,03500
Other Expenses 1,390.95.617-1,318.111.820.446.871.737.269.8-63.247.333.159.1-105.382.961.245.8-4660.849.543.617.0738.813.94.80-19.7122.61
Operating Expenses 1,390.9649.81,181.51,322.61,762.91,671.11,658.71,663.41,500.41,500.4441.81,714.61,710.21,633.7701.31,610.51,533.81,411.7407.21,416.61,369.91,376.7229.221,399.21,375.41,239.81,28573.381,070.96
Operating Income 359.7168.5-137.9-1,876.5126-67.9270241.926.6-155.8-142.9-1,252.8434.8637.4748.8779.5700.2575.7307.4538.2445.2407.9544.58407.6287.3269.925483.33203.09
Operating Income Ratio 0.1040.046-0.053-0.7540.03-0.0190.0710.0610.008-0.047-0.044-1.2490.1080.1570.1860.1830.1760.1650.1270.1570.1270.1240.170.1140.0840.0890.0830.2090.079
Total Other Income Expenses Net -279.6-303.1-1,528.7-876.9-296.6-225.7-219.6-236.4-219.6-155.2-167.1-146.1-138-136.3-182.6-121.6-132.5-152.5-128.4-124.9-153.4-142.9-283.05-186.6-185.5-177.4-170122.64-15.72
Income Before Tax 80.1-134.6-1,666.6-2,753.4-170.6-293.650.45.5-193-311-310-1,398.9296.8501.1566.2657.9567.7423.2179413.3291.8265261.53221101.892.584205.97187.37
Income Before Tax Ratio 0.023-0.037-0.635-1.107-0.04-0.0830.0130.001-0.057-0.094-0.096-1.3940.0740.1240.140.1540.1430.1210.0740.120.0830.080.0820.0620.030.0310.0280.5170.072
Income Tax Expense 3.20887.9259.641-102.512.8-1.2-93.2-144.5-221.947.132.858.90.10.10.80.50.960.5343.4-0.438.96.371.7213.7729.2
Net Income 80.1-134.6-2,553.4-2,753.4-171.6-195.537.64.5-99.6-164.318.8-1,398.7297.1501.3566.5658566.7422.8178.2413.6289.1265.2263.27220.985.325.663202.04158.26
Net Income Ratio 0.023-0.037-0.972-1.107-0.04-0.0550.010.001-0.029-0.050.006-1.3940.0740.1240.1410.1540.1430.1210.0730.120.0820.080.0820.0620.0250.0080.0210.5070.061
EPS 2.54-3.5-65.37-76.49-4.77-5.431.050.13-2.77-4.570.53-38.938.2713.9515.918.4719.2115.756.041611.2110.298.928.963.460.232.556.8514.13
EPS Diluted 2.54-3.5-65.37-76.49-4.77-5.431.050.13-2.77-4.560.52-38.938.2213.8815.917.2917.2514.746.0415.2411.1610.228.928.953.460.232.556.8514.13
EBITDA 616.3419.2114.6-1,616.9388.1211.6534.5521.7312.9195.3242.2-921.1751.7973.31,046.51,136.31,037.4883.8519.7837.4729.7680.4619.45658.5494.9465.8333.1888.48364.98
EBITDA Ratio 0.1780.1150.044-0.650.0910.060.140.1320.0920.0590.075-0.9180.1870.240.260.2660.2610.2540.2140.2440.2080.2060.1930.1850.1450.1540.110.2220.141